NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to ...
The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...
The KP.3 variant of SARS-CoV-2 is dominating in Canada right now, accounting for the majority of the COVID-19 cases in the ...
NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...
An experimental Moderna mRNA vaccine for mpox has demonstrated greater effectiveness than current shots in reducing disease ...
Health Canada authorized Moderna's updated COVID-19 vaccine on Tuesday to roll out in fall and winter immunization campaigns.
Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.